Quest Diagnostics and NewYork-Presbyterian, or NYP, announced a strategic agreement designed to broaden access to quality, innovative laboratory services for the providers and patients of NewYork-Presbyterian primarily in New York as well as the Tri-State Area and beyond. Under a definitive agreement, Quest will acquire select assets of the laboratory services business of NewYork-Presbyterian. NewYork-Presbyterian will still own and operate world-renowned hospital labs, including its anatomic pathology services, to continue providing high quality, complex clinical laboratory services with its academic partners. The parties expect to complete the transaction in the second quarter of 2023, pending customary regulatory approvals. Financial details of the transaction were not disclosed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics and NewYork-Presbyterian Agree to Laboratory Services Transaction
- Quest Diagnostics raises quarterly dividend, increases share repurchase program
- Quest Diagnostics sees FY23 adjusted EPS $8.40-$9.00, consensus $8.69
- Quest Diagnostics reports Q4 adjusted EPS $1.98, consensus $1.91
- QUEST DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; PROVIDES GUIDANCE FOR FULL YEAR 2023